GENE ONLINE|News &
Opinion
Blog

2025-10-12|

AI Enhances Accuracy of Skull Stripping in Neuroimaging for Studying Brain Across Lifespan

by Mark Chiang
Share To

A recent study by researchers Wang, Wang, and Zuo has introduced advancements in the use of artificial intelligence (AI) to improve skull stripping, a critical neuroimaging technique. The findings highlight how AI can enhance the accuracy and efficiency of this process, which is essential for analyzing brain structures across different stages of human life. The research underscores the potential for AI-driven methods to refine imaging techniques used in neuroscience and biomedical engineering.

Skull stripping involves separating the brain from non-brain tissues in neuroimaging scans, a step crucial for studying brain anatomy and function. The researchers demonstrated that their AI-based approach significantly improves this process by providing more precise results compared to traditional methods. This advancement could enable better understanding of brain development, aging, and neurological disorders. The study emphasizes the role of AI in addressing challenges associated with analyzing complex datasets across diverse populations and age groups.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: October 12, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
LATEST
Wendy Short Bartie Repositions Bristol Myers Squibb Corporate Affairs to Integrate Patient Advocacy and Healthcare Access
2026-09-14
Wendy Short Bartie Restructures Bristol Myers Squibb Corporate Affairs to Link Reputation with Business Performance
2026-09-14
Wendy Short Bartie Integrates Patient Advocacy and Public Trust into Bristol Myers Squibb Business Strategy
2026-09-14
Mycenax Teams Up with Global Partners to Expedite R&D and Market Launch of Next-Generation ADCs
2026-09-14
Chinese Bispecific Antibody Tops Keytruda in First Head-to-Head OS Win; SMA Muscle-Strengthening Therapy Approved, B7-H3 ADC Shows Promise
2026-09-14
FDA Approves Bayer’s Sevabertinib as First-Line Treatment for Adults Living with HER2-Mutant Lung Cancer
2026-09-14
Takeda R&D President Andy Plump and GV Managing Partner Krishna Yeshwant Announce Retirements
2026-09-12
Scroll to Top